12.06.2023 22:58:31
|
Ironwood Pharma's Pediatric Functional Constipation Treatment Gets FDA Approval
(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD), Monday announced that the U.S. Food and Drug Administration has approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages 6-17 years old with functional constipation.
Linzess is the first and only FDA-approved prescription therapy for functional constipation in this patient population.
Earlier this year, the FDA granted a 6-month priority review to supplemental New Drug Application, 4 months earlier than the standard review timeline.
Linzess is developed and marketed by AbbVie and Ironwood Pharmaceuticals in the United States.
Functional constipation in children is a chronic condition characterized by hard, infrequent bowel movements that are often difficult or painful to pass2. The condition affects an estimated 6 million children ages 6-17 years-old in the U.S.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Ironwood Pharmaceuticals Inc (A)mehr Nachrichten
06.11.24 |
Ausblick: Ironwood Pharmaceuticals A vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Ironwood Pharmaceuticals Inc (A)mehr Analysen
Aktien in diesem Artikel
Ironwood Pharmaceuticals Inc (A) | 1,91 | -0,52% |
|